GENITOURINARY DRUGS:
TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA (BPH) OR LOWER URINARY TRACT SYMPTOMS (LUTS)

	5 ALPHA REDUCTASE INHIBITORS		ALPHA 1 ADRENERGIC RECEPTOR BLOCKERS (non-selective)		ALPHA 1 ADRENERGIC RECEPTOR BLOCKERS (selective)			PDE5 INHIBITORS
	DUTASTERIDE (Avodart)	FINASTERIDE (Proscar)	DOXAZOSIN (Cardura)	TERAZOSIN (Hytrin)	ALFUZOSIN (Xatral)	SILODOSIN (Rapaflo)	TAMSULOSIN (Flomax CR)	TADALAFIL (Cialis) 5 mg daily dose ONLY*
INTEGRASE INHIBITORS								
• DOLUTEGRAVIR (Tivicay, Triumeq)	√	√	√	√	√	√	√	√
• ELVITEGRAVIR / COBICISTAT (Stribild, Genvoya)	⚠ Potential for ↑ dutasteride	√	⚠ Potential for ↑ doxazosin	⚠ Potential for ↑ terazosin	X Potential for ↑ alfuzosin concentrations and toxicity	⚠ Potential for ↑ silodosin. Use 4 mg dose and monitor for toxicity	⚠ Potential for ↑ tamsulosin. Use 0.4 mg dose and monitor for toxicity	Potential for ↑ tadalafil but dose adjustment not required (*for 5 mg daily dose only)
• RALTEGRAVIR (Isentress)	√	√	√	√	√	√	√	√
PROTEASE INHIBITORS								
RITONAVIR (Norvir) or cobicistat-boosted PIs, e.g.: • ATAZANAVIR (Evotaz, Reyataz) • DARUNAVIR (Prezcobix, Prezista) • LOPINAVIR (Kaletra)	⚠ Potential for ↑ dutasteride	√	⚠ Potential for ↑ doxazosin	⚠ Potential for ↑ terazosin	X Potential for ↑ alfuzosin concentrations and toxicity	⚠ Potential for ↑ silodosin. Use 4 mg dose and monitor for toxicity	⚠ Potential for ↑ tamsulosin. Use 0.4 mg dose and monitor for toxicity	Potential for ↑ tadalafil but dose adjustment not required (*for 5 mg daily dose only)

	5 ALPHA REDUCTASE INHIBITORS		ALPHA 1 ADRENERGIC RECEPTOR BLOCKERS (non-selective)		ALPHA 1 ADRENERGIC RECEPTOR BLOCKERS (se lective)			PDE5 INHIBITORS
	DUTASTERIDE (Avodart)	FINASTERIDE (Proscar)	DOXAZOSIN (Cardura)	TERAZOSIN (Hytrin)	ALFUZOSIN (Xatral)	SILODOSIN (Rapaflo)	TAMSULOSIN (Flomax CR)	TADALAFIL (Cialis) 5 mg daily dose only*
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS								
• RILPIVIRINE (Complera, Edurant)	√	√	√	√	√	√	√	√
• EFAVIRENZ (Sustiva, Atripla) • ETRAVIRINE (Intelence) • NEVIRAPINE (Viramune)	⚠ Potential for ↓ dutasteride	√	⚠ Potential for ↓ doxazosin	⚠ Potential for ↓ terazosin	⚠ Potential for ↓ drug concentrations			⚠ Potential for ↓ drug concentrations

*NB: For tadalafil, this table refers to the daily dose of 5 mg for benign prostatic hyperplasia. Please refer to **"Genitourinary Drugs: PDE5 Inhibitors for Erectile Dysfunction (ED) or Pulmonary Arterial Hypertension (PAH)"** table for recommendations on higher or intermittent dosing of tadalafil with antiretrovirals.

NOTES

GENITOURINARY DRUGS:
TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA (BPH) OR LOWER URINARY TRACT SYMPTOMS (LUTS)

Mechanism of Drug Interactions, Management and Monitoring

	5 ALPHA REDUCTASE INHIBITORS		ALPHA 1 ADRENERGIC BLOCKERS (non-selective)		ALPHA 1 ADRENERGIC BLOCKERS (selective)		PDE5 INHIBITOR TADALAFIL 5 mg daily dose ONLY*
MECHANISM OF INTERACTION	Inhibition of CYP3A4 (dutasteride)	Induction of CYP3A4 (dutasteride)	Inhibition of CYP3A4 (doxazosin, terazosin)	Induction of CYP3A4 (doxazosin, terazosin)	Inhibition of CYP3A4 (alfuzosin, silodosin, tamsulosin)	Induction of CYP3A4 (all)	Inhibition of CYP3A4 (tadalafil)
MAIN INTERACTING ARVs	Ritonavir and cobicistat-boosted protease inhibitors and elvitegravir	Most NNRTIs	Ritonavir and cobicistat-boosted protease inhibitors and elvitegravir	Most NNRTIs	Ritonavir and cobicistat-boosted protease inhibitors and elvitegravir	Most NNRTIs	May be used with all ARVs. *Please refer to **"Genitourinary Drugs: PDE5 Inhibitors for Erectile Dysfunction (ED) or Pulmonary Arterial Hypertension (PAH)"** table for recommendations on higher or intermittent dosing of tadalafil with antiretrovirals
MANAGEMENT	Finasteride may be used	Finasteride may be used	Adjust dose according to efficacy/toxicity		Alfuzosin: consider low-dose silodosin or tamsulosin with monitoring or change antiretroviral regimen		Daily tadalafil 5 mg may be used without dose adjustment. May ↓ to 2.5 mg daily based on tolerability
MONITORING	Dutasteride toxicity: erectile dysfunction, decreased libido	Dutasteride efficacy	Toxicity: hypotension, dizziness, headache, asthenia, nasal congestion	Doxazosin & terazosin efficacy	Toxicity: hypotension, dizziness, headache, diarrhea, nasal congestion	Alfuzosin, silodosin, tamsulosin efficacy	Monitor for toxicity: headache, dyspepsia, flushing, back pain, nasal congestion

A MANAGEMENT TOOL FOR HIV DRUG-DRUG INTERACTIONS

Printed with the assistance of an unrestricted educational grant from:

© 2016 The Canadian HIV/AIDS Pharmacists Network (CHAP)
All listed brands are trademarks or registered trademarks of their respective owners.